Does percutaneous mitral-valve repair in addition to medical therapy reduce the rate of death or unplanned hospitalization for heart failure at 1 year in patients with severe secondary mitral regurgitation?
Percutaneous mitral-valve repair added to medical therapy did not significantly reduce death or heart failure hospitalization at 1 year compared to medical therapy alone in patients with severe secondary mitral regurgitation.
Among patients with severe secondary mitral regurgitation, the rate of death or unplanned hospitalization for heart failure at 1 year did not differ significantly between patients who underwent percutaneous mitral-valve repair in addition to receiving medical therapy and those who received medical therapy alone. (Funded by the French Ministry of Health and Research National Program and Abbott Vascular; MITRA-FR ClinicalTrials.gov number, NCT01920698 .).
“The take-home message is that in the first good prospective randomized trial of catheter treatment of functional mitral regurgitation, percutaneous mitral valve repair was of no benefit for hard endpoints.”
Obadia et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: